Ad Header



The Pulse of the Pharmaceutical Industry

Late-stage Dupixent trials show positive results

Written by: | | Dated: Tuesday, October 16th, 2018


Sanofi, Regeneron say late-stage Dupixent trials show positive results


PARIS, Oct 16 (Reuters) – Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues.

Sanofi and Regeneron said in a joint statement that two pivotal Phase 3 placebo-controlled trials evaluating Dupixent (dupilumab), in adults with inadequately controlled chronic rhinosinusitis with nasal polyps, had met all primary and secondary endpoints.

The U.S. Food & Drug Administration regulator is expected to approve Dupixent for asthma treatment before the year-end.


(Reporting by Sudip Kar-Gupta, Editing by Sherry Jacob-Phillips)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom